Ceralasertib (AZD6738)

For research use only.

Catalog No.S7693

48 publications

Ceralasertib (AZD6738) Chemical Structure

CAS No. 1352226-88-0

Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 297 In stock
USD 197 In stock
USD 697 In stock
USD 1470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Ceralasertib (AZD6738) has been cited by 48 publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
Targets
ATR [1]
(Cell-free assay)
1 nM
In vitro

In four Kras mutant cell lines: H23, H460, A549, and H358, AZD6738 inhibits ATR kinase activity and impairs cell viability. In ATM-deficient H23 cells, AZD6738 strongly synergizes with cisplatin to induce rapid cell death. [1] In p53 or ATM defective cells, AZD6738 treatment results in replication fork stalls and accumulation of unrepaired DNA damage, resulting in cell death by mitotic catastrophe. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LICR-LON-HN4 and LICR-LON-HN5 cells NVjNWVRPTnWwY4Tpc44h[XO|YYm= NVTndmN2OC5yMzygNE4yNCByLkOsJFEtKDNuIEGwJO69VQ>? NFfjb41CYkR4N{O4JIlvcGmkaYTpc44hd2ZiQWTSJJRpem:3Z3igcI9{eyCxZjDkc5dve3S{ZXHtJJBpd3OyaH;yfYxifGmxbjDv[kBEUEtzIH;uJHNmejN2NT6= MoG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUe4PVAoRjNyMEW3PFkxRC:jPh?=
K8484 cells M2nOc2Z2dmO2aX;uJIF{e2G7 NHTifY0zKM7:TR?= MlLnO{Bpd3W{cx?= NXfrS484UW5iS{i0PFQh[2WubIOsJGFbTDZ5M{igZZQhOiEEtV2gZ49ueGyndHXsfUBxemW4ZX70[YQh\2WvY3n0ZYJqdmVvaX7keYNm\CCFaHuxJJBpd3OyaH;yfYxifGmxbjDvckBU\XKrbnWgN|Q2NCC2aHWg[I94dnO2cnXhcUBCXFJidHHy[4V1Ng>? MlLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6OUG0PFgoRjJ7OEmxOFg5RC:jPh?=
SNU-601 cells NF;SOI9E\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6 MU[wMVEh|ryvb3yvUC=> NHnKVHU2KGSjeYO= NFf3PJBVcGViUzDhcoQhe3WkLVexJJBweHWuYYTpc45{KG:oIGPOWU03ODFiY3XscJMhf2W{ZTDkdoFu[XSrY3HscJkh[W6mIHTvd4Uu\GWyZX7k[Y51dHliaX7jdoVie2WmIHL5JGFbTDZ5M{iu Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzM{iwN|QoRjJ6MUO4NFM1RC:jPh?=
breast cancer cell lines NV3YTmxUS2WubDDndo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWfTR294OC5zMkWsJFAvOjVuIECuOUBidmRiMT6wJO69VQ>? M2ntZ|Uh\GG7cx?= M4nX[2lEPTBidnHseYV{KHKjbnfl[EBnem:vIECuN{B1dyB-MTFOwI1wdC:O NF7tb|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{WwNVEyOyd-Mke1NFEyOTN:L3G+
LoVo cells MlfrSpVv[3Srb36gZZN{[Xl? NVLEfJc4OjRiaB?= MVzS[YR2[3Srb36gbY4h[2WubDDjc5VvfDtiYTDwdo9xd3K2aX;uJI9nKHSqZTDj[YxtKHCxcIXsZZRqd25iYYLlJEhqdiCjZHTpeIlwdiC2bzDj[YxtKGO7Y3zlJIFzemW|dDmgeY5l\XKpb3nu[{BieG:ydH;zbZMhf2inbjDlfJBwe2WmIITvJIRzfWdiYYSgZ49v[2WwdILheIlwdnNiZ4LlZZRmeiC2aHHuJFPjiIoQvF2= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNzMEOxNkc,OjZ|MUCzNVI9N2F-
HT29 cells NUX0VZduTnWwY4Tpc44h[XO|YYm= MlKzOlAhdWmwcx?= M4LWSmlEPTBiPTCwMlA4PCEQvF2= NV3sdYZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>
LoVo cells NYexd41{S3m2b4TvfIlkcXS7IHHzd4F6 MUS3NkBpenN? NVexVVlTT0l3MDC9JFAvPDRizszN MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2Nke3Nkc,OzB|NE[3O|I9N2F-
LoVo cells NYHTTHdSTnWwY4Tpc44h[XO|YYm= Mn2wNlUhdWdxa3e= NX3QeZFMQCCqcoO= Mlv6R5AhRSByLke0JO69VQ>? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2Nke3Nkc,OzB|NE[3O|I9N2F-
LoVo cells MX\GeY5kfGmxbjDhd5NigQ>? M2j0N|UxKG2pL3vn MUG4JIhzew>? NGfVRWtEeCB;IEKuNkDPxE1? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2Nke3Nkc,OzB|NE[3O|I9N2F-
HT-29 cells NHfZZmREgXSxdH;4bYNqfHliYYPzZZk> NGLQOFc4OiCqcoO= NHPIOGZIUTVyIE2gNk43KM7:TR?= MkC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|NE[3O|IoRjNyM{S2O|czRC:jPh?=
LoVo cells NEDYdnBHfW6ldHnvckBie3OjeR?= NGPUXos4PSCvZz;r[y=> M3XUPFghcHK| MXvDdEA:KDJwNjFOwG0> NWT3N2RvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>
MDA-MB-468 cells NXznVmFCTnWwY4Tpc44h[XO|YYm= MnXFTWM2OCB;IEWuO{DPxE1? NX;uXGV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOFY4PzJpPkOwN|Q3Pzd{PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ATM pSer1981 / ATM / ATR / Chk1 pSer345 / Chk1 / Chk2 pThr68 / Chk2; 

PubMed: 26563132     


TP53/ATM wild-type (TP53/ATM-wt) primary CLL cells cocultured with and CLL cells, both CII-GFPsh and CII-ATMsh were treated with AZD6738 (1 μM) for 2 hours, or left untreated, prior to exposure to HU (1 mM) or IR (6 Gy) for a further 5 hours. AZD6738 treatment inhibited ATR signaling as indicated by a reduction in HU-induced Chk1 phosphorylation (lanes 3 vs 4 and 9 vs 10). In ATM-proficient CLL cells, this also led to ATM activation as evidenced by ATM phosphorylation and Chk2 phosphorylation (lane 3 vs 4). 

pCHK1 / pCDC25c / pRPA32 / γH2AX / pHH3 / cleaved caspase-3 / RAD51; 

PubMed: 29605721     


MDA-231 or Hs578t cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. After treatment, western blot was performed using anti-γH2AX, anti-pCHK1 (S345), anti-CHK1, anti-pCDC25c (S216), anti-CDC25c, anti-pHH3, anti-RAD51 anti-pRPA32 (S4/S8), anti-cleaved-caspase 3, and anti-GAPDH antibodies. 

26563132 29605721
Immunofluorescence
53BP1; 

PubMed: 26563132     


Cells treated with AZD6738 (1 μM) for 48 hours were labeled with anti-53BP1 antibodies, and at least 200 cells were then analyzed in each sample using a ×60 lens. AZD6738 treatment led to an accumulation of 53BP1 foci in Mec1 and ATMi pretreated CII cells and an accumulation of 53BP1 bodies in CII cells without ATMi pretreatment.

γH2AX / RAD51; 

PubMed: 29605721     


MDA-231 cells were treated with 50 nM or 100 nM of AZD1775 with or without 500 nM of AZD6738 for 24 h. Cells were probed with anti-γH2AX and anti-RAD51 antibodies. Scale bar: 5 μm. 

26563132 29605721
Growth inhibition assay
IC50; 

PubMed: 28062704     


Cell line IC50 values assessed for growth inhibition in a 72-hour MTT assay

Cell viability; 

PubMed: 26563132     


CII-GFPsh, CII-ATMsh (ATM-deficient), and Mec1 (p53-defective) cells were treated with AZD6738 for 4 days, and viability was measured using the CellTiter-Glo assay. Surviving fraction is expressed relative to untreated controls. AZD6738 induced significantly greater dose-dependent cytotoxicity with significantly lower AZD6738 EC50 in CII-ATMsh and Mec1 cells compared with CII-GFPsh cells.

28062704 26563132
In vivo In nude mice bearing H460 and H23 tumors, AZD6738 (50 mg/kg, p.o.) results in tumor growth inhibition (TGI), and the the combination with cisplatin causes rapid regression of ATM-deficient H23 tumors. [1] In nude mice bearing LoVo xenografts, a combination of AZD6738 (50 mg/kg) + IR (2 Gy) avoids toxicity while still maintaining efficacy. [3]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: H23, H460, A549, and H358 cells
  • Concentrations: ~30 μM
  • Incubation Time: 48 h
  • Method: Cells are treated in white walled, clear bottom 96-well plates with the indicated doses of AZD6738, cisplatin, gemcitabine, or combination for 48 h. ATP levels are assessed as surrogate measure of viability is assessed using the CellTiter-Glo Luminescent Cell Viability Assay and Safire2 plate reader. Raw data are corrected for background luminescence prior to further analysis. For AZD6738 treatment, log dose response curves are generated in GraphPad Prism 6 by nonlinear regression (log(inhibitor) vs. response with variable slope) of log-transformed (x = log(x)) data normalized to the mean of untreated controls. GI50 values, defined as the dose X at which Y = 50%, were extrapolated from dose response curves.
    (Only for Reference)
Animal Research: [1]
- Collapse
  • Animal Models: Female athymic nude mice bearing H23 or H460 xenografts
  • Dosages: 25 or 50 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (198.78 mM)
Water Insoluble
Ethanol '41 mg/mL warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% propylene glycol+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 412.51
Formula

C20H24N6O2S

CAS No. 1352226-88-0
Storage powder
in solvent
Synonyms N/A
Smiles CC1COCCN1C2=NC(=NC(=C2)C3(CC3)S(=N)(=O)C)C4=C5C=CNC5=NC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04704661 Not yet recruiting Drug: Ceralasertib|Biological: Trastuzumab Deruxtecan Advanced Breast Carcinoma|Advanced Colorectal Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Unresectable Colorectal Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 8 2021 Phase 1
NCT04361825 Enrolling by invitation Drug: Durvalumab Small Cell Lung Cancer Samsung Medical Center|AstraZeneca June 17 2020 Phase 2
NCT04298008 Recruiting Drug: AZD6738|Drug: Durvalumab Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital June 25 2020 Phase 2
NCT04298021 Recruiting Drug: AZD6738|Drug: Durvalumab|Drug: Olaparib Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital June 25 2020 Phase 2
NCT03669601 Recruiting Drug: AZD6738|Drug: Gemcitabine Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust October 15 2019 Phase 1
NCT03770429 Recruiting Drug: AZD6738 Leukemia|Myelodysplastic Syndrome Massachusetts General Hospital|AstraZeneca August 5 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

Related ATM/ATR Products

Tags: buy Ceralasertib (AZD6738) | Ceralasertib (AZD6738) supplier | purchase Ceralasertib (AZD6738) | Ceralasertib (AZD6738) cost | Ceralasertib (AZD6738) manufacturer | order Ceralasertib (AZD6738) | Ceralasertib (AZD6738) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID